TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells

X. Wu, P. R. Blackburn, R. C. Tschumper, Stephen C Ekker, Diane F Jelinek

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a clonal plasma cell malignancy that is initiated by a number of mutations and the process of disease progression is characterized by further acquisition of mutations. The identification and functional characterization of these myelomagenic mutations is necessary to better understand the underlying pathogenic mechanisms in this disease. Recent advancements in next-generation sequencing have made the identification of most of these mutations a reality. However, the functional characterization of these mutations has been hampered by the lack of proper and efficient tools to dissect these mutations. Here we explored the possible utility of transcription activator-like effector nuclease (TALEN) genome engineering technology to tailoring the genome of MM cells. To test this possibility, we targeted the HPRT1 gene and found that TALENs are a very robust and efficient genome-editing tool in MM cells. Using cotransfected green fluorescent protein as an enrichment marker, single-cell subclones with desirable TALEN modifications in the HPRT1 gene were obtained in as little as 3-4 weeks of time. We believe that TALENs will greatly facilitate the functional study of somatic mutations in MM as well as other cancers.

Original languageEnglish (US)
Article number210
JournalBlood Cancer Journal
Volume4
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Multiple Myeloma
Mutation
Genome
Green Fluorescent Proteins
Plasma Cells
Transcription Activator-Like Effector Nucleases
Genes
Disease Progression
Neoplasms
Technology

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells. / Wu, X.; Blackburn, P. R.; Tschumper, R. C.; Ekker, Stephen C; Jelinek, Diane F.

In: Blood Cancer Journal, Vol. 4, No. 5, 210, 2014.

Research output: Contribution to journalArticle

@article{e5682e4b44714c88989f339e9c5c04ba,
title = "TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells",
abstract = "Multiple myeloma (MM) is a clonal plasma cell malignancy that is initiated by a number of mutations and the process of disease progression is characterized by further acquisition of mutations. The identification and functional characterization of these myelomagenic mutations is necessary to better understand the underlying pathogenic mechanisms in this disease. Recent advancements in next-generation sequencing have made the identification of most of these mutations a reality. However, the functional characterization of these mutations has been hampered by the lack of proper and efficient tools to dissect these mutations. Here we explored the possible utility of transcription activator-like effector nuclease (TALEN) genome engineering technology to tailoring the genome of MM cells. To test this possibility, we targeted the HPRT1 gene and found that TALENs are a very robust and efficient genome-editing tool in MM cells. Using cotransfected green fluorescent protein as an enrichment marker, single-cell subclones with desirable TALEN modifications in the HPRT1 gene were obtained in as little as 3-4 weeks of time. We believe that TALENs will greatly facilitate the functional study of somatic mutations in MM as well as other cancers.",
author = "X. Wu and Blackburn, {P. R.} and Tschumper, {R. C.} and Ekker, {Stephen C} and Jelinek, {Diane F}",
year = "2014",
doi = "10.1038/bcj.2014.32",
language = "English (US)",
volume = "4",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells

AU - Wu, X.

AU - Blackburn, P. R.

AU - Tschumper, R. C.

AU - Ekker, Stephen C

AU - Jelinek, Diane F

PY - 2014

Y1 - 2014

N2 - Multiple myeloma (MM) is a clonal plasma cell malignancy that is initiated by a number of mutations and the process of disease progression is characterized by further acquisition of mutations. The identification and functional characterization of these myelomagenic mutations is necessary to better understand the underlying pathogenic mechanisms in this disease. Recent advancements in next-generation sequencing have made the identification of most of these mutations a reality. However, the functional characterization of these mutations has been hampered by the lack of proper and efficient tools to dissect these mutations. Here we explored the possible utility of transcription activator-like effector nuclease (TALEN) genome engineering technology to tailoring the genome of MM cells. To test this possibility, we targeted the HPRT1 gene and found that TALENs are a very robust and efficient genome-editing tool in MM cells. Using cotransfected green fluorescent protein as an enrichment marker, single-cell subclones with desirable TALEN modifications in the HPRT1 gene were obtained in as little as 3-4 weeks of time. We believe that TALENs will greatly facilitate the functional study of somatic mutations in MM as well as other cancers.

AB - Multiple myeloma (MM) is a clonal plasma cell malignancy that is initiated by a number of mutations and the process of disease progression is characterized by further acquisition of mutations. The identification and functional characterization of these myelomagenic mutations is necessary to better understand the underlying pathogenic mechanisms in this disease. Recent advancements in next-generation sequencing have made the identification of most of these mutations a reality. However, the functional characterization of these mutations has been hampered by the lack of proper and efficient tools to dissect these mutations. Here we explored the possible utility of transcription activator-like effector nuclease (TALEN) genome engineering technology to tailoring the genome of MM cells. To test this possibility, we targeted the HPRT1 gene and found that TALENs are a very robust and efficient genome-editing tool in MM cells. Using cotransfected green fluorescent protein as an enrichment marker, single-cell subclones with desirable TALEN modifications in the HPRT1 gene were obtained in as little as 3-4 weeks of time. We believe that TALENs will greatly facilitate the functional study of somatic mutations in MM as well as other cancers.

UR - http://www.scopus.com/inward/record.url?scp=84902013041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902013041&partnerID=8YFLogxK

U2 - 10.1038/bcj.2014.32

DO - 10.1038/bcj.2014.32

M3 - Article

C2 - 24813078

AN - SCOPUS:84902013041

VL - 4

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 5

M1 - 210

ER -